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Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is a biomarker of acute kidney injury (AKI), and
levels reflect severity of disease in critically ill patients. However, continuous venovenous hemofiltration (CVVH)
may affect plasma levels by clearance or release of NGAL by activated neutrophils in the filter, dependent on the
anticoagulation regimen applied. We therefore studied handling of NGAL by CVVH in patients with AKI.
Methods: Immediately before initiation of CVVH, prefilter blood was drawn. After 10, 60, 180, and 720 minutes
of CVVH, samples were collected from pre- and postfilter (in- and outlet) blood and ultrafiltrate. CVVH with the
following anticoagulation regimens was studied: no anticoagulation in case of a high bleeding tendency (n = 13),
unfractionated heparin (n = 8), or trisodium citrate (n = 21). NGAL levels were determined with enzyme-linked
immunosorbent assay (ELISA).
Results: Concentrations of NGAL at inlet and outlet were similar, and concentrations did not change over time in
any of the anticoagulation groups; thus no net removal or production of NGAL occurred. Concentrations of NGAL
at inlet correlated with disease severity at initiation of CVVH and at the end of a CVVH run. Concentrations of
NGAL in the ultrafiltrate were lower with citrate-based CVVH (P = 0.03) and decreased over time, irrespective of
anticoagulation administered (P < 0.001). The sieving coefficient and clearance of NGAL were low and decreased
over time (P < 0.001).
Conclusions: The plasma level and biomarker value of NGAL in critically ill patients with AKI are not affected by
CVVH, because clearance by the filter was low. Furthermore, no evidence exists for intrafilter release of NGAL by
neutrophils, irrespective of the anticoagulation method applied.Introduction
Acute kidney injury (AKI) is common in critically ill
patients, particularly in case of sepsis, and associated
with increased morbidity and mortality, even in the long
term [1]. The diagnosis of AKI heavily relies on serum
creatinine (sCr) and urinary output, but these markers* Correspondence: louiseschilder@hotmail.com
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AKI. In patients with subclinical AKI, further damage
may be prevented by appropriate measures. Therefore,
biomarkers to predict AKI before the increase of sCr
have been studied intensively. Neutrophilic gelatinase-
associated lipocalin (NGAL) is a small, 25-kDa protein
and one of the neutrophil secondary granule proteins
[2]. It is also rapidly induced in distal tubular segments
of injured nephrons with stress [3]. Therefore, urinary
and plasma levels are helpful in early prediction of AKIl Ltd. This is an Open Access article distributed under the terms of the Creative
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related outcomes, such as the need for renal-replacement
therapy (RRT), as well as mortality [5-7,9-12]. Also, levels
of NGAL are associated with disease severity, and its levels
are more profoundly elevated during sepsis [5,7,11,13-15].
However, it remains to be elucidated whether continuous
venovenous hemofiltration (CVVH) in the treatment of
AKI affects plasma NGAL levels and thus the biomarker
value, either by clearance, adsorption, or production of
NGAL in the filter. One study described removal of
NGAL by filtration and possibly adsorption in vitro [16].
A small in vivo series (n = 3) reported on NGAL levels in
the ultrafiltrate of patients with AKI taking citrate-based
CVVH; the clearance of NGAL was low, and the inlet
concentration of NGAL over 24 hours of CVVH did not
decline [17].
However, plasma NGAL may decline after just one
session of hemodialysis [18]. Conversely, release of NGAL
by neutrophils has been reported in extracorporeal circu-
lation during cardiac surgery [19]. Additionally, the antic-
oagulation regimen applied during CVVH could influence
release by neutrophils and handling of NGAL by the filter
and extracorporeal circuit. Moreover, it has been postu-
lated that citrate prevents degranulation of neutrophils
induced by heparin, complement activation, and blood-
filter contact during CVVH, partly by chelating calcium,
necessary for neutrophil degranulation [20,21].
The aim of the current study was to assess whether
NGAL is cleared by CVVH sufficiently to affect its
plasma levels and biomarker value in critically ill patients
with AKI. We further hypothesize that citrate-based
CVVH diminishes release of NGAL by neutrophils in the
extracorporeal circuit and filter.
Materials and methods
The patient population and methods for this study are
reported elsewhere [22,23]. Patients for this companion
study were recruited during office hours for sampling
when participating in one of the two following pros-
pective studies. The first study started 1 year before the
availability of a custom-made citrate-based replacement
fluid. From March 2004 to September 2005, patients ad-
mitted to the intensive care unit (ICU) who developed
AKI necessitating CVVH, but in whom heparin was
contraindicated because of a high bleeding tendency,
were either treated by anticoagulant-free CVVH (n = 13)
or, after becoming available in 2005, by regional citrate
anticoagulation (n = 10) and were prospectively moni-
tored. High risk for bleeding was arbitrarily defined as a
platelet count of less than 40 × 109/L, an activated partial
thromboplastin time (aPTT) of more than 60 seconds,
a prothrombin time of more than 2.0 international
normalized ratio, recent major bleeding, or active
bleeding. Because all patients were treated accordingto local standards, the need for informed consent was
waived for this study.
Patients were also recruited from a second study, a
multicentered randomized controlled trial initiated in
2006 (the so-called Citrate Anticoagulation versus Sys-
temic Heparinization, CASH trial, clinicaltrials.gov num-
ber NCT00209378). Patients admitted to the ICU who
developed AKI necessitating CVVH without a high bleed-
ing risk, were randomized between unfractionated heparin
as anticoagulant (n = 8) or citrate (n = 11). Only patients
from our hospital were studied for this companion study.
Informed consent was obtained from all study participants
or their next-of-kin. Study protocols were approved by the
local medical ethical committee (VU University Medical
Ethical Committee) and performed in accordance with the
Declaration of Helsinki. We pooled the studies because of
the mechanistic nature of the current article, without
focus on patient-centered outcomes.
Treatment protocol
The indication for CVVH was based on standard clinical
criteria that include AKI accompanied by hemodynamic
instability, ongoing hypercatabolism, diuretic-resistant
fluid overload, respiratory distress, multiorgan failure, or
some combinations of these factors. CVVH was perfor-
med by using a hemofiltration machine (DIAPACT; B.
Braun Medical, Melsungen, Germany). Vascular access
was obtained by the insertion of an 11 F double-lumen
catheter (GAMCATH; Gambro, Hechingen, Germany)
into the femoral, subclavian, or jugular vein. A 1.9 m2
highly permeable cellulose triacetate filter (NIPRO
UF-205; Nissho Corp., Osaka, Japan, cut-off approxi-
mately 40 kDa) was used in all treatments. For lactate- or
bicarbonate-based CVVH, commercially prepared buffer
solutions were used (BH504 or HF32bic, respectively;
Dirinco, Rosmalen, The Netherlands). Patients with high
serum lactate levels (>5 mM) were routinely treated with
bicarbonate-buffered rather than lactate-buffered CVVH.
For the use of citrate, a replacement solution was custom-
made by Dirinco (Rosmalen, The Netherlands). Blood-
flow rate was set at 180 ml/min in all groups. Replacement
fluid was administered at a standard rate of 2,000 ml/h in
the patients receiving no anticoagulation or heparin with
bicarbonate or lactate-containing replacement fluids.
Replacement-fluid rate in the citrate group was set at
2,400 ml/h, and, in all cases, replacement fluids were
infused in predilutional mode. Patients taking heparin
were administered a heparin bolus of 5,000 IU followed by
a body weight-based continuous infusion targeting an
aPTT between 45 and 55 seconds. Patients receiving
citrate-based therapy had a separate intravenous infusion
with calcium glubionate (Calcium Sandoz, containing
0.225 mM calcium; Novartis Consumer Health, Breda,
The Netherlands). Calcium administration was adapted to
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especially designed algorithm, as described before [22].
The target ionized calcium concentration in the circuit
was 0.3 mM, but not routinely monitored, because this is
almost uniformly achieved with the aforementioned
settings [22].
Study protocol
At inclusion, demographic variables were recorded, such
as age, gender, and reason for ICU admission. Assess-
ment of disease severity on ICU admission was done
according to the Acute Physiology And Chronic Health
Evaluation II (APACHE II), the Simplified Acute Physi-
ology Score II (SAPS II), and the Sequential Organ Failure
Assessment score (SOFA). Patients had not yet received
renal-replacement therapy previously, and in 40 (96%) of
42 patients, the first filter run was studied; in two patients,
a later filter run was studied because of technical reasons.
We collected systemic inflammatory response syndrome
(SIRS) criteria: body temperature >38°C; a heart rate of >90
beats/min; a respiratory rate of >20 breaths/min or mech-
anical ventilation; and white blood cell counts of <4.0 ×
109/L or >12.0 × 109/L. When SIRS (two or more criteria)
and an infection were present (either clinically suspected
or microbiologically confirmed), patients were classified
as having sepsis. Venous blood samples were collected
from the hemofiltration catheter from each patient before
the initiation of CVVH and administration of heparin.
Heparin was given immediately after filter connection.
Thereafter, blood samples were collected at 10, 60, 180,
and 720 minutes from the pre- and postfilter pole, or until
the filter terminated, if occurring within 720 minutes. A
time period up to 720 minutes was chosen because we
expected clearance of NGAL to occur early after initiation
of CVVH before filter saturation occurred. Prefilter blood
was invariably drawn before addition of replacement
fluids, and thus, reported concentrations of NGAL at inlet
are not diluted. Leukocytes, platelets, and serum crea-
tinine concentrations were measured before initiation of
CVVH and routinely thereafter. In all patients, a zero
fluid balance was achieved during the time points at
which blood samples were drawn. Ultrafiltrate samples
were collected from the appropriate ports. Samples were
collected in standard Vacutainer tubes (Becton Dickinson,
Erembodegem, Belgium) with ethylenediaminetetraacetic
acid (EDTA), benzamidine, and soybean trypsin inhibitor
added. All samples were centrifuged at 1,300 g for 10 mi-
nutes at 4°C and stored at −80°C until assayed in 2009.
Measurements and calculations
NGAL concentrations were measured with enzyme-linked
immunosorbent assays (ELISAs). Commercially available
antibody duosets were used (R&D Systems, UK, Lipocalin-
2/NGAL Duoset, DY1757). Plasma samples and ultrafiltratewere measured in separate assays with NGAL standards
prepared in appropriate matrix solutions, 0.5% bovine
albumin serum in phosphate-buffered saline or fresh
ultrafiltrate. All measurements were done according to
the protocols provided by the manufacturer. The lower
detection limit of NGAL was approximately 30 ng/ml.
Each sample was run in duplicate, and the mean concen-
tration was calculated. Formulas used to evaluate fluxes
are described in the following list:
Formulas used to evaluate fluxes
Qi = Qb × (1-Ht), Qo = Qi
Mi = Qi × Ci
Mo = Qo × Co
Muf = Quf × Cuf
Mtr =Mi - Mo
Mad =Mtr - Muf
C = Ci × Qi/(Qi + RF)
SC = 2 × Cuf/(C + Co)
Abbreviations
Ci, Concentration in inlet plasma before addition of
replacement fluid (ng/ml)
Co, Concentration in outlet plasma (ng/ml)
Cuf, Concentration in ultrafiltrate (ng/ml)
Qb, Inlet blood-flow rate (ml/min)
Qi, Inlet plasma-flow rate (ml/min)
Qo, Outlet plasma-flow rate (ml/min)
Quf, Ultrafiltration flow rate (ml/min)
Mi, Mass inlet rate (ng/min)
Mo, Mass outlet rate (ng/min)
Muf, Mass ultrafiltration rate (ng/min)
Mtr, Mass removal rate (ng/min)
Mad, Mass adsorption rate (ng/min)
C, Concentration in inlet plasma after addition of
replacement fluid (ng/ml)
RF, Replacement fluid-flow rate (ml/min)
SC, Sieving coefficient
Statistical analysis
Because of mostly non-gaussian distributions, data are
presented as median and range. No baseline differences
were found between the two separate citrate groups (cit-
rate versus no-anticoagulation and citrate versus heparin),
so the citrate data were pooled. When appropriate, data
were log-transformed to achieve normal distributions.
The values for the total mass-production rate and mass-
adsorption rate were ranked, because some values were
negative and could not be log-transformed. Group differ-
ences were evaluated by using χ2 or Kruskal-Wallis tests,
where appropriate. To evaluate differences according to
anticoagulation regimens in time, we used generalized es-
timating equations (GEEs), taking repeated measurements
in the same patient into account. The focus of GEEs is on
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and time points, and their first-order interaction (that is,
differences between anticoagulation groups over time), and
associated P values are reported. Spearman correlation
coefficients were used to express relations. A P < 0.05 was




At baseline, all patients included in this study (n = 42)
met the criteria for SIRS, and 18 (43%) of 42 patients
met the criteria for sepsis. The no-anticoagulation group
(n = 13) had higher SAPS II and SOFA scores than did
the other groups. The creatinine concentration at base-
line was lower in the no-anticoagulation group than in
the other groups, as were platelet levels. The prescribed
dose was 22 (16 to 32) ml/kg/h in the no-anticoagulation
group, 22 (11 to 32) ml/kg/h in the heparin group, and 23
(16 to 31) ml/kg/h in the citrate group (P = 0.68). No off
time and no net fluid removal occurred during the study
period, so the delivered dose equaled the prescribed dose.
The median survival time of the filter was 10 (3 to 66)
hours in the no-anticoagulation group, 17 (1 to 70) hours
in the heparin group, and 45 (five to 138) in the citrate
group (P = 0.03). In 13 (31%) of 42 patients, the filter
terminated within 720 minutes; seven (54%) of 13 in the
no-anticoagulation group, three (38%) of eight in the
heparin group, and three (14%) of 21 in the citrate group
(P < 0.001) (Table 1).
NGAL was detectable in all plasma and ultrafiltration
samples. The concentrations of NGAL at inlet, outlet, and
in the ultrafiltrate over time during CVVH are presented
in Figure 1. Concentrations at inlet and outlet were similar
and did not change over time in any of the anticoagulation
groups. Concentrations of NGAL in the ultrafiltrate were
lower in the citrate group (P = 0.03) and decreased over
time in all groups (P < 0.001). The total mass removal rate
and total mass adsorption rate did not differ between
groups and remained unchanged over time (Figure 2).
The sieving coefficient was low and did not differ between
groups, with medians ranging from 0.2 to 0.4. The sieving
coefficient decreased over time in all groups (P < 0.001).
Also, the clearance of NGAL, calculated from sieving
coefficient times ultrafiltration rate (corrected for predilu-
tion), was similar in groups and decreased over time in all
groups (P < 0.001); from 6 (2 to 44) to 2 (0 to 6) ml/min in
the no-anticoagulation group, from 10 (four to 18) to
3 (0 to 16) ml/min for heparin and from 8 (0 to 40)
to 4 (1 to 9) ml/min in citrate-based CVVH. Results
of an analysis excluding all patients in whom sample
collection could not be completed because of premature
filter termination did not differ from those of an analysis
of all patients (data not shown).Correlations
No correlation was noted between NGAL and creatinine
levels at initiation of CVVH (P = 0.53). Plasma levels of
NGAL at inlet at the start of CVVH correlated with
those at the end of the CVVH run (rs = 0.88, P < 0.001).
Also, plasma levels of NGAL at inlet at initiation of CVVH
correlated with APACHE II scores (rs = 0.30, P = 0.05),
SAPS II scores (rs = 0.36, P = 0.03) and SOFA scores
(rs = 0.32, P = 0.04) at admission, and plasma levels of
NGAL at the end of the CVVH run persistently cor-
related with these disease-severity scores (for APACHE II,
rs = 0.35, P = 0.03, for SAPS II, rs = 0.28, P = 0.08, and for
SOFA, rs = 0.33, P = 0.04).
Sepsis and mortality
When analyzing all measured concentrations at inlet,
concentrations of NGAL did not differ between patients
with sepsis (879 (77 to 9,070) ng/ml) and patients with-
out sepsis (544 (56 to 2,460), P = 0.14). Sixteen (38%) of
the 42 patients died in the ICU. There was a trend for
higher plasma levels of NGAL at inlet in nonsurvivors at
initiation of CVVH; 1,035 (121 to 9,070) ng/ml versus
607 (56 to 3,950) ng/ml in survivors (P = 0.11). This
trend persisted at the end of the CVVH run; 896 (44 to
4,370) ng/ml versus 451 (91 to 4,640) ng/ml in survivors
(P = 0.07), because no decrease in NGAL was noted over
time (P = 0.32).
Discussion
The present study shows that plasma NGAL levels in
critically ill patients with AKI are not affected by CVVH,
irrespective of the anticoagulation applied.
Among biomarkers for early detection of AKI and its
severity, NGAL is probably most studied, whereas pre-
dictive values vary among studies [9,10]. Plasma levels
are usually more elevated with increasing disease sever-
ity, in patients with sepsis (versus nonsepsis), and in
those destined to die, even during RRT [5-7,9-12]. Con-
versely, low values may help predict recovery from AKI
after discontinuation of RRT [12]. Because CVVH could
influence plasma levels of NGAL and thus its predictive
value, by clearance or by production of NGAL in the
filter, we studied handling of NGAL in patients receiving
CVVH.
Concentrations of NGAL at inlet before addition of
replacement fluid, representing patient’s plasma levels,
did not change over time and correlated with disease
severity irrespective of a CVVH run. Our results are in
concordance with a small series of patients (n = 3) with
AKI taking citrate-based CVVH, where inlet concentra-
tions of NGAL over 24 hours of RRT did not decline
[17]. Four patients had plasma NGAL levels at initiation
of CVVH of <150 ng/ml, which is low, given the reported
cut-off values of approximately 150 ng/ml for predictive
Table 1 Patient characteristics
No anticoagulation Heparin Citrate
n = 13 n = 8 n = 21 P
Sex, male 7 (54) 6 (75) 14 (75) 0.59
Age, years 70 (34–84) 57 (23–81) 64 (32–84) 0.49
Weight, kg 70 (50–100) 74 (55–135) 78 (60–110) 0.41
Reason for admission 0.29
Respiratory 2 (15) 5 (63) 7 (33)
Circulatory 3 (23) 1 (13) 4 (19)
Trauma 2 (15) 0 1 (5)
Post-CPR 2 (15) 0 2 (10)
Postoperative 4 (31) 1 (13) 7 (33)
AKI 0 1 (13) 0
Vasopressor dependent 13 (100) 6 (75) 16 (76) 0.15
Mechanical ventilation 11(85) 8 (100) 19 (91) 0.51
Sepsis 5 (39) 5 (63) 8 (38) 0.46
APACHE II at ICU admission 28 (11–42) 22 (15–37) 25 (14–41) 0.47
SAPS II at ICU admission 75 (43–112) 47 (37–77) 52 (32–86) 0.002
SOFA at ICU admission 14 (7–21) 11 (8–15) 13 (8–18) 0.02
ICU stay, days 5 (2–82) 20 (4–48) 20 (3–81) 0.08
LOS in ICU at start CVVH, days 1 (1–5) 2 (1–4) 2 (0–14) 0.74
Biochemical data
Creatinine at start, μΜ 249 (100–410) 420 (156–626) 326 (47–622) 0.01
Creatinine 24 hours, μM 206 (140–250) 284 (125–463) 232 (46–441) 0.05
Urea at start, mM 21 (6–48) 32 (12–97) 21 (6–41) 0.25
Urea 24 hours, mM 17 (6–34) 17 (11–102) 14 (6–28) 0.24
Leukocytes at start, ×109 8 (1–17) 12 (7–20) 12 (1–26) 0.29
Leukocytes 24 hours, ×109 10 (1–26) 13 (6–26) 11 (2–28) 0.85
Platelets at start, ×109 65 (22–173) 167 (44–352) 118 (35–332) 0.03
Platelets 24 hours, ×109 59 (13–148) 117 (27–239) 105 (5–349) 0.02
Median (and range) or number (percentage). AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, cardiopulmonary
resuscitation; ICU, intensive care unit; LOS, length of stay; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment score.
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assessment can override the predictive value of NGAL
in deciding on initiation of CVVH.
Concentrations of NGAL measured at the outlet were
similar to those at the inlet in all groups, suggesting that
no net removal or production of NGAL occurred during
CVVH. Overall, the sieving coefficient and clearance of
NGAL were lower than expected, based on its molecular
size, yet in concordance with results of others [16,17].
By binding to other molecules, NGAL may exceed size
limits for passage through the filter. It also seems pos-
sible that adsorption contributed to a low sieving co-
efficient, even though calculated adsorption rates were
very low. However, neither low clearance nor absorp-
tion resulted in net removal of NGAL during CVVH,
so that we cannot formally exclude concomitant produc-
tion, for instance via release by activated neutrophils.Moreover, any production in the filter could be offset by
adsorption.
We cannot judge the inhibitory effect of citrate on
neutrophil activation in this respect, because we did not
observe net production of NGAL in the filter in any of
the anticoagulation groups. Concentrations of NGAL
in the ultrafiltrate were lowest in the citrate group,
but this could partly be explained by dilution due to
higher ultrafiltration rates. Dissimilar degranulation pat-
terns of primary and secondary granules of neutrophils
might account for the absence of NGAL release in the
filter, because primary granular markers elastase and mye-
loperoxidase (MPO) are released during heparin-CVVH,
whereas secondary granular NGAL apparently is not [20].
Others observed that there was lower release of lacto-
ferrin, a secondary granular product similar to NGAL,
than of MPO during citrate-based dialysis [24].
Figure 1 Concentration of NGAL during CVVH over time (median and interquartile range) at inlet (before addition of replacement
fluid), outlet, and ultrafiltrate. Symbols: ● no anticoagulation, ■ heparin,▲citrate. Levels of NGAL at inlet and outlet were similar across groups
and did not change over time. Levels of NGAL in the ultrafiltrate were lower in the citrate group (P = 0.03) and decreased over time in all groups
(P < 0.001).
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tively small size of groups and the absence in part of
randomization, explaining some baseline differences
among the groups. Patients in the no-anticoagulation
group did not receive anticoagulation because of a bleed-
ing tendency and were more severely ill, demonstrated byFigure 2 Mass removal rate, mass adsorption rate, sieving coefficient
interquartile range). Symbols: ● no anticoagulation, ■ heparin,▲citrate.
groups and did not change over time. Sieving coefficient and clearance dehigher SAPS II and SOFA scores at baseline and lower
platelet counts. We cannot exclude earlier start of CVVH
in the no-anticoagulation group than in the other groups,
because initial creatinine was lower, but this does not
invalidate our conclusions of this pathophysiologic study.
We have evaluated the course of study variables for up to, and clearance of NGAL during CVVH over time (median and
Total mass-removal rate and mass-adsorption rate were similar across
creased over time in all groups (P < 0.001).
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exclude changes beyond that time interval or subsequent
CVVH runs.
Conclusions
The biomarker value of NGAL in critically ill patients
with AKI are not affected by CVVH, because clearance
by the filter was low. Therefore, plasma levels of NGAL
may be used for prognostication in patients receiving
CVVH. Furthermore, probably no intrafilter release of
NGAL by neutrophils occurs, irrespective of the anticoa-
gulation method applied.
Key messages
 Plasma levels of NGAL in critically ill patients with
acute kidney injury correlate with disease severity
at initiation of CVVH and at the end of the a
CVVH run
 No net removal of NGAL is found during CVVH,
and therefore plasma levels of NGAL may be used
for prognostication
 No evidence exists for production of NGAL in
the filter by neutrophils, irrespective of the type
of anticoagulation applied
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